ESMO WCGIC 2020 | Nivolumab for CCA

Richard D. Kim • 3 Jul 2020

ESMO WCGIC 2020

Bile Duct Cancer Gastrointestinal Cancer Antibodies FOLFOX Nivolumab

ABC-06 Immuno-Oncology

Richard Kim, MD, of the Moffitt Cancer Center, Tampa, FL, describes Phase II results of nivolumab in patients with advanced, refractory cholangiocarcinoma (CCA). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

The latest in targeted therapies for advanced colorectal cancer

Richard D. Kim • 26 Jan 2023

HIMALAYA: tremelimumab + durvalumab in unresectable HCC

Richard D. Kim • 27 Jan 2022

Biomarkers of treatment response in patients with MMR-proficient CRC

Richard D. Kim • 26 Jan 2023

Immunotherapy plus TKIs for the treatment of CRC

Richard D. Kim • 27 Jan 2022

Related Videos

Novel developments in HCC treatment

Daneng Li • 6 Jul 2020

COVID-19 & the management of cancer patients

Alberto F. Sobrero • 3 Jun 2020

HER-2 conversion: a phenomenon in trastuzumab resistance

Russell Petty • 5 Nov 2019

The gut microbiome: role in causing and detecting colorectal cancer

Paul O'Toole • 29 Nov 2018